Topic
Psychotropic drug
About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: It is suggested that increased medial thalamic creatine-phosphocreatine concentrations in patients with untreated obsessive-compulsive disorder reflect altered energy use in the medialThalamus and might differentiate patients with obsessive- compulsive disorder from healthy controls and patients with major depression.
Abstract: Altered brain creatine-phosphocreatine levels might reflect changes in brain energy use and have been implicated in the pathogenesis of obsessive-compulsive disorder and major depressive disorder. We used proton magnetic resonance spectroscopy to measure absolute concentrations of creatine-phosphocreatine in the right and left medial thalami in 18 pediatric patients with major depressive disorder 9 to 17 years of age, 18 case-matched healthy controls, and 27 patients with obsessive-compulsive disorder 7 to 16 years old. The two patient groups were psychotropic drug naive and were not comorbid for the diagnosis of the comparison group. We found significantly increased left and right medial thalamic creatine-phosphocreatine concentrations in patients with obsessive-compulsive disorder compared with both healthy controls and patients with major depression. Creatine-phosphocreatine concentrations did not differ significantly between patients with major depression and healthy controls. Our data suggest that increased medial thalamic creatine-phosphocreatine concentrations in patients with untreated obsessive-compulsive disorder reflect altered energy use in the medial thalamus and might differentiate patients with obsessive-compulsive disorder from healthy controls and patients with major depression. Although these results must be considered preliminary, further study of the diagnostic specificity of creatine-phosphocreatine in obsessive-compulsive disorder is indicated.
78 citations
01 Jan 1983
TL;DR: Methods to study brain histamine receptors provide additional means of assessing the roles of histamine in brain, and a description of these receptors, some of their associated effects, and their response to psychotropic drugs is presented.
Abstract: While mounting evidence is elevating histamine to the category of a putative neurotransmitter, its explicit functions in brain remain as unclear as those of most other putative neurotransmitters. Evidence has been reviewed (Green et al., 1978a; Schwartz, 1979, Schwartz et al., 1980a,b; Hough and Green, 1980) that it may function in arousal, locomotor activity, regulation of hunger and thirst, emesis, thermoregulation, and the elaboration of hormones, most persuasively, of prolactin and the antidiuretic hormone. There is also evidence, too rich to review here, that histamine may alter the formation, release, or activities of other endogenous substances. As provocative as many of these observations are, they remain to be integrated into coherent hypotheses, as do observations on other biogenic amines. The development of methods to measure histamine metabolism (Hough et al., 1981) offers an opportunity to evaluate further the functions of histamine in brain. Methods to study brain histamine receptors provide additional means of assessing the roles of histamine in brain. A description of these receptors, some of their associated effects, and their response to psychotropic drugs is presented in this review.
77 citations
TL;DR: Findings indicate that experimental manipulations, stress, and psychotropic drug application have a time lag on bio-behavioral parameters which should be considered when studying animal behavior in response to stressors and/or to drug treatment.
77 citations
TL;DR: The detection of mescaline in two different samples, both analysed by two methods based on different principles, is reliable evidence for the presence of this psychotropic drug, which seems to be the oldest plant drug that yielded a major bioactive compound on chemical analysis.
77 citations
TL;DR: In an 8-week, open-label trial, lamotrigine was added to ongoing psychotropic drug regimens in schizophrenia and schizoaffective disorder patients with clinically significant OCS and was safe and well tolerated.
Abstract: Obsessive-compulsive symptoms (OCS) are clinically important phenomena in schizophrenia patients. Lamotrigine has a modulating effect on glutamatergic neurotransmission relevant to pathophysiology of both schizophrenia and OCD. Efficacy and tolerability of lamotrigine in schizophrenia and schizoaffective patients with comorbid OCS were evaluated. In an 8-week, open-label trial, lamotrigine (25 mg/day for 1 week, 50 mg for 2 weeks, 100 mg for 2 weeks, 200 mg for 3 weeks) was added to ongoing psychotropic drug regimens in schizophrenia (N = 5) and schizoaffective disorder (N = 6) patients with clinically significant OCS [Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score > 16]. The Y-BOCS score for nine completers decreased significantly from baseline to week 8 (22.9 +/- 6.1 vs 17.4 +/- 3.6; t = 2.33, df = 1, P = 0.033). Five patients, all with schizoaffective disorder, were responders (>or=35% decrease in Y-BOCS score). No significant changes were detected in schizophrenia symptom severity. Depressive symptoms, assessed with the Calgary Depression Rating Scale, improved significantly (6.4 +/- 1.5 vs 4.0 +/- 2.5; t = 3.19, df = 1, P = 0.013); this change positively correlated with OCS improvement (r = 0.69, P = 0.04). Lamotrigine was safe and well tolerated. Explicit evaluation of therapeutic efficacy of adjunctive lamotrigine in schizoaffective disorder patients with comorbid OCS merits further investigation.
76 citations